Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Dateline City:
KENILWORTH, N.J.
First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and Diverse Oncology Pipeline
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from a Phase 2 trial evaluating the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate in Merck’s oncology pipeline, for the treatment of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
Language:
English
Contact:
Media Contacts:
Pamela Eisele
(267) 305-3558
Kristen Drake
(908) 740-1679
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
